⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 12, 2024Clinical Cancer Research

Eftilagimod alpha (soluble LAG-3 protein) combined with pembrolizumab as second-line therapy for patients with metastatic head and neck squamous cell carcinoma

Martin Förster Irene Braña Antonio López–Pousa Bernard Doger Patricia Roxburgh Pawan Bajaj Julio A. Peguero Matthew Krebs Enric Carcereny Grisma Patel Christian Mueller Chrystelle Brignone Frédéric Triebel

View at Publisher

Ask AI

Bookmark

Share

Abstract

Eftilagimod alpha (efti), a soluble LAG3 protein, activates antigen-presenting cells (APC) and downstream T cells. TACTI-002 (part C) evaluated whether combining efti with pembrolizumab led to strong antitumor responses in patients with second-line recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) while demonstrating good tolerability.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Förster et al. (2024) studied this question.

synapsesocial.com/papers/68e60785b6db64358759ada2 https://doi.org/10.1158/1078-0432.ccr-24-0473

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Data from Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma2024
2AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.2024 · 5 citations
3Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients.Late-Phase Clinical Trial · 2026
4Abstract PS1-09-16: Optimal biological dose of eftilagimod alpha, a soluble LAG-3 protein, in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-003RCT · 2026
5200P Testing a higher dose (90 mg s.c.) of eftilagimod alpha, a soluble LAG-3 protein in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-0032024

More related papers

Combination of anlotinib and sintilimab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma: a single-arm prospective study2024
A randomized, non-comparative, multicenter phase II trial of neoadjuvant becotatug vedotin alone or combined with immune checkpoint inhibitors (penpulimab/ivonescimab) in resectable locally advanced head and neck squamous cell carcinoma.2026
Evaluation of autologous tumor-infiltrating lymphocytes (GT201) plus toripalimab in recurrent or metastatic head and neck cancer.2026

More from Clinical Cancer Research

Serial circulating tumour DNA monitoring in first-line advanced NSCLC (COPE): a randomized, two-arm non-comparative phase II trialWed,
DuoBody®-FAPαxDR4 is a novel DR4 agonist that induces potent antitumor activity through FAPα-dependent, DR4-transactivation-mediated apoptosisWed,